Screener
BioMarin Pharmaceuticals BMRN Business Segments — Net Income
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by BioMarin Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:NetIncomeLoss.
The source filing: BioMarin Pharmaceuticals’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 4:14 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001048477-26-000016
| Line item | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Other income, net | 3,279 | 4,833 | 7,240 | 2,879 |
| INCOME BEFORE INCOME TAXES | 61,384 | 297,868 | 202,587 | 535,957 |
| Provision for income taxes | 16,622 | 57,336 | 52,298 | 109,739 |
| NET INCOME | $44,762 | $240,532 | $150,289 | $426,218 |
| EARNINGS PER SHARE, BASIC | $0.23 | $1.25 | $0.78 | $2.23 |
| EARNINGS PER SHARE, DILUTED | $0.23 | $1.23 | $0.77 | $2.19 |
| Weighted average common shares outstanding, basic | 193,423 | 191,907 | 192,959 | 191,440 |
| Weighted average common shares outstanding, diluted | 194,467 | 197,091 | 194,147 | 196,643 |
Item 1. Financial Statements
FAQ
- What is BioMarin Pharmaceuticals's business segments — net income?
- BioMarin Pharmaceuticals (BMRN) reported business segments — net income of $44.76M in Q2 2026.
- How has BioMarin Pharmaceuticals's business segments — net income changed year-over-year?
- BioMarin Pharmaceuticals's business segments — net income decreased by 81.4% year-over-year, from $240.53M to $44.76M.
- What is the long-term trend for BioMarin Pharmaceuticals's business segments — net income?
- Over 2 years (2022 to 2024), BioMarin Pharmaceuticals's business segments — net income has grown at a 73.6% compound annual growth rate (CAGR), from $141.56M to $426.86M.
- What does business segments — net income mean?
- This represents the final profitability of the reportable segment after accounting for all revenues and associated operating expenses. It serves as the primary measure of the segment's financial performance and its contribution to the overall company's bottom line. It reflects the net result of commercial success and operational cost management.
Ask your AI about BioMarin Pharmaceuticals's business segments — net income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude